BLA 761097 · Regeneron Pharmaceuticals
Libtayo
Cemiplimab-Rwlc · Intravenous
NovelBreakthrough therapyAccelerated approvalPriority reviewLast checked: Nov 20, 2026Latest source record: Aug 31, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Sep 28, 2018
Approved uses
11
Original approval plus efficacy supplements
Registered trials
221
19 Phase 3, 87 recruiting
FAERS reports
2,083
1,728 serious, 438 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 31, 2026.
LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated: Cutaneous Squamous Cell Carcinoma (CSCC) for the treatment of adult patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. ( 1.1 ) for the adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation. ( 1.1 , 14.1 ) Basal Cell Carcinoma (BCC) for the treatment of adult patients with locally advanced or metastatic BCC (laBCC or mBCC) who have been previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate. ( 1.2 ) Non-Small Cell Lung Cancer (NSCLC) in combination with platinum‐based chemotherapy for the first‐line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. ( 1.3 ) as single agent for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) ≥50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. ( 1.3 , 2.1 ) 1.1 Cutaneous Squamous Cell Carcinoma LIBTAYO is indicated for the treatment of adult patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. LIBTAYO is indicated for the adjuvant treatment of adult patients with CSCC at high risk of recurrence [see Clinical Studies (14.1) ]...
Mechanism: Binding of the PD-1 ligands PD-L1 and PD-L2 to the PD-1 receptor found on T cells inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Cemiplimab-rwlc is a recombinant human immunoglobulin G4 (IgG4) monoclonal antibody that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models,...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 29, 2025 Supplement 32 · Efficacy · priority review LetterLabel
- Oct 8, 2025 Supplement 30 · Efficacy · priority review LabelMedication GuideLetter
- Apr 5, 2024 Supplement 23 · Efficacy LetterLabel
- Apr 28, 2023 Supplement 16 · Efficacy LetterLabelMedication Guide
- Apr 28, 2023 Supplement 15 · Efficacy LetterLabel
- Nov 8, 2022 Supplement 14 · Efficacy LabelLetter
- Feb 22, 2021 Supplement 7 · Efficacy · priority review LabelLetter
- Feb 9, 2021 Supplement 8 · Efficacy · priority review LabelLetter
- Feb 9, 2021 Supplement 9 · Efficacy · priority review LabelLetter
- Jun 25, 2020 Supplement 5 · Efficacy LabelLetter
- Sep 28, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalLetterLabelReview
1 products under this application
- LIBTAYO · CEMIPLIMAB-RWLC 350MG · INJECTABLE, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cemiplimab" as an intervention, any sponsor and status, largest first.
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
- A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With SurgeryPivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05608291 · 1,564 participants · Start Jan 16, 2023 · Primary completion Jan 15, 2027
Drug: Fianlimab; Cemiplimab and 2 more · For: Melanoma
Sites: La Jolla, California; San Francisco, California; Santa Monica, California · 211 sites in all
- Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic MelanomaPivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05352672 · 1,546 participants · Start Jul 14, 2022 · Primary completion Mar 12, 2026
Drug: Fianlimab; Cemiplimab and 2 more · For: Melanoma
Sites: La Jolla, California; Los Angeles, California; Orlando, Florida · 210 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT03564340 · 890 participants (planned) · Start May 21, 2018 · Primary completion May 10, 2027
Drug: Ubamatamab; Cemiplimab and 2 more · For: Recurrent Ovarian Cancer; Recurrent Fallopian Tube Cancer; Recurrent Primary Peritoneal Cancer and 3 more
Sites: Birmingham, Alabama; Boston, Massachusetts; Rochester, Minnesota · 54 sites in all
- Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung CancerPivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT03409614 · 789 participants · Start Mar 6, 2018 · Primary completion Feb 27, 2025
Drug: REGN2810; REGN2810/chemo/ipi and 1 more · For: Non-small Cell Lung Cancer
Sites: Rancho Mirage, California; Riverside, California; Whittier, California · 133 sites in all
- Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)Pivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT03088540 · 712 participants · Start May 29, 2017 · Primary completion Apr 18, 2025
Drug: Pemetrexed; Paclitaxel and 4 more · For: Carcinoma,Non-Small-Cell Lung; Lung Carcinomas, Non-Small-Cell; Non-small-cell Lung Carcinoma and 1 more
Sites: Albury, Australia; Wollongong, Australia; Fitzroy, Australia · 192 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT04590326 · 612 participants (planned) · Start Dec 8, 2020 · Primary completion Nov 8, 2028
Drug: REGN5668; Cemiplimab and 3 more · For: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer and 1 more
Sites: Duarte, California; Irvine, California; Orange, California · 28 sites in all
- Study of Cemiplimab in Adults With Cervical CancerPivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT03257267 · 608 participants · Start Sep 5, 2017 · Primary completion Mar 15, 2021
Drug: Cemiplimab; Investigator Choice (IC) Chemotherapy · For: Squamous Cell Carcinoma (SCC); Recurrent or Metastatic, Platinum-refractory Cervical Cancer
Sites: Phoenix, Arizona; Tucson, Arizona; Orange, California · 105 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death176
- disease progression155
- off label use107
- fatigue88
- rash86
- dyspnoea65
- pyrexia64
- pruritus53
- interstitial lung disease50
- myocarditis50
- asthenia47
- drug ineffective47
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 7 |
| 2019 | 138 |
| 2020 | 105 |
| 2021 | 204 |
| 2022 | 292 |
| 2023 | 258 |
| 2024 | 345 |
| 2025 | 435 |
| 2026 | 299 |
Recalls
1 FDA enforcement reports for this application.
Jul 28, 2026 · Class II · Ongoing
Lack of Assurance of Sterility
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Libtayo (Cemiplimab-Rwlc)
2024 spending
$12.6M
Beneficiaries
212
1,232 claims
Per beneficiary
$59,295
$1,458.64 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,875,102 |
| 2021 | $1,897,142 |
| 2022 | $2,697,847 |
| 2023 | $5,887,092 |
| 2024 | $12,570,559 |
Part B: Libtayo (Cemiplimab-Rwlc) · HCPCS J9119
2024 spending
$348M
Beneficiaries
5,482
35,522 claims
Per beneficiary
$63,500
2024 ASP limit $27.74 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $155,476,305 |
| 2021 | $179,470,041 |
| 2022 | $203,832,304 |
| 2023 | $270,188,134 |
| 2024 | $348,106,559 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma.
Rischin D, Porceddu S, Day F, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Immune Checkpoint Inhibitor-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis.
Nielsen DL, Juhl CB, Nielsen OH, et al. · JAMA Oncol 2024 · Systematic Review, Meta-Analysis
- Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.
Gogishvili M, Melkadze T, Makharadze T, et al. · Nat Med 2022 · Randomized Controlled Trial, Clinical Trial, Phase III
- Systemic treatment of immune checkpoint inhibitor-induced psoriasis: Inference-based guidance.
Papp KA, Puig L, Beecker J, et al. · J Eur Acad Dermatol Venereol 2025 · Systematic Review
- Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Sezer A, Kilickap S, Gümüş M, et al. · Lancet 2021 · Clinical Trial, Phase III, Multicenter Study
- Survival with Cemiplimab in Recurrent Cervical Cancer.
Tewari KS, Monk BJ, Vergote I, et al. · N Engl J Med 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Regeneron
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.